2. Search Result
Search Result
Results for "

maximal electroshock (MES)

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W097106
    (S)-3-N-Cbz-Amino-succinimide

    		Drug Isomer Neurological Disease
    (S)-3-N-Cbz-Amino-succinimide (Compound 1d) is an antiepileptic agent that can inhibit pentylenetetrazole (PTZ) and maximal electroshock (MES)-induced tonic convulsions in mice .
    (S)-3-N-Cbz-Amino-succinimide
  • HY-W012481
    Nirvanol

    Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin

    		 Drug Metabolite Neurological Disease
    Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the Maximal Electroshock (M.E.S.) seizure model in mice. The ED50 of Nirvanol is 23 mg/kg (measured 30 minutes after intraperitoneal injection) and 30 mg/kg (measured 2 hours after intraperitoneal injection). Nirvanol shows potential for research in epilepsy-related neurological disorders .
    Nirvanol
  • HY-148135
    hCAI/II-IN-6

    		Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-170801
    Anticonvulsant agent 7

    		Others Neurological Disease
    Anticonvulsant agent 7 (Compound 19) is an orally active broad-spectrum anticonvulsant that demonstrates excellent anticonvulsive activity in both the MES (maximal electroshock seizure) and 6 Hz epilepsy modelsmouse .
    Anticonvulsant agent 7
  • HY-106424
    Soretolide

    		Others Neurological Disease
    Soretolide is an antiepileptic agent. Soretolide is effective in maximal electroshock-induced seizure (MES) test in rodents. Soretolide inhibits metabolism of Phenytoin (HY-B0448). Soretolide exhibits a good pharmacokinetic character in rats model .
    Soretolide
  • HY-168773
    (R)-AS-1

    		EAAT Neurological Disease
    (R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC50 of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED50s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .
    (R)-AS-1
  • HY-172887
    Kv7.2/Kv7.3 activator-2

    		Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC50: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .
    Kv7.2/Kv7.3 activator-2